Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 161
Healthy volunteers: no

Brief summary:
This trial is conducted in Europe.

This is a clinical trial investigating the effectiveness and the safety of using biphasic insulin aspart 30 both for initiation and intensification of insulin treatment in type 2 diabetes.

Detailed description:

Arms:
arm 1: Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).

Interventions: intervention 1: biphasic insulin aspart
Intervention descriptions: intervention 1: Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)

Protocol document: